Core Insights - Four Seasons Pharmaceutical (00460) reported a mid-year performance for 2025, with revenue of 1.146 billion RMB, a year-on-year increase of 20.69% [1] - The company achieved a profit attributable to shareholders of 103 million RMB, recovering from a loss of 33.424 million RMB in the same period last year [1] - Basic earnings per share were 1.11 cents, and the company proposed an interim cash dividend of 0.99 cents per share [1] Revenue Growth - The increase in revenue was primarily driven by the medical aesthetics business, which generated approximately 585 million RMB, up about 81.3% from 323 million RMB in the same period of 2024 [1] - The significant growth in medical aesthetics sales was attributed to strategic partnerships and an upgraded marketing strategy for the company's medical aesthetics platform, Meiyan Space [1] R&D and Product Development - Innovation and product matrix enhancement are core competitive engines for Meiyan Space [2] - Meiyan Space has established five R&D platforms focusing on international innovative materials, regenerative materials, HA products, biopolymers, and composite innovative materials [2] - The company has a professional R&D team of over 80 members, advancing the development and registration of over 60 medical aesthetic products, covering categories such as injections, photonic devices, weight loss drugs, and skincare products [2] - Recent breakthroughs include the approval of two self-developed regenerative injection products: polycaprolactone microsphere facial filler (Youth Needle) and polylactic acid facial filler (Childlike Needle) [2]
四环医药发布中期业绩 股东应占溢利1.03亿元 同比扭亏为盈